| Literature DB >> 33923467 |
Ting Xiao1,2,3, Zhonghua Luo2, Zhenghong Guo4, Xude Wang2, Meng Ding2, Wei Wang2, Xiangchun Shen1,3, Yuqing Zhao2,5.
Abstract
This study aimed to investigate the protective effect of black raspberry anthocyanins (BRAs) against acute and subacute alcoholic liver disease (ALD). Network analysis and docking study were carried out to understand the potential mechanism. Thereafter, the serum biochemical parameters and liver indexes were measured, the histopathological changes of the liver were analyzed in vivo. The results showed that all tested parameters were ameliorated after the administration of BRAs with alcohol. Meanwhile, there was increased protein expression of NF-κB and TGF-β in extracted livers, which was associated with hepatitis and hepatic fibrosis. Furthermore, BRAs and cyanidin-3-O-rutinoside exhibited cytotoxic effects on t-HSC/Cl-6, HepG2, and Hep3B and induced the apoptosis of HepG2 cells; downregulated the protein expression level of Bcl-2; upregulated the level of Bax; and promoted the release of cytochrome C, cleaved caspase-9, cleaved caspase-3, and cleaved PARP in HepG2 cells. In addition, the antioxidant activity of BRAs was tested, and the chemical components were analyzed by FT-ICR MS. The results proved that BRAs exert preventive effect on ALD through the antioxidant and apoptosis pathways.Entities:
Keywords: alcoholic liver injury; anthocyanins; antioxidant; apoptosis; black raspberry
Mesh:
Substances:
Year: 2021 PMID: 33923467 PMCID: PMC8073606 DOI: 10.3390/molecules26082313
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis ((A) hepatitis, (B) hepatic fibrosis, and (C) liver cancer). (a,e,i) The enriched terms in biological process (BP); (b,f,j) the enriched terms in cellular component (CC); (c,g,k) the enriched terms in molecular function (MF); (d,h,l) the enriched terms in KEGG.
Molecular docking mode for anthocyanins with Bcl-2, Caspase 9, and Cytochrome c.
| Targets | Compound | Binding Free Energy (kcal/mol) | Numbers of Bonds |
|---|---|---|---|
| Bcl-2 | Cyanidin- | −7.3 | 6 |
| Cyanidin- | −8.2 | 11 | |
| Cyanidin- | −8.3 | 11 | |
| Caspase 9 | Cyanidin- | −7.6 | 4 |
| Cyanidin- | −8.0 | 6 | |
| Cyanidin- | −8.3 | 9 | |
| Cytochrome c | Cyanidin- | −7.2 | 5 |
| Cyanidin- | −7.7 | 9 | |
| Cyanidin- | −7.7 | 10 |
Figure 2Bioactive compound–protein docking combination: (a) Cyanidin-3-O-glucoside, (b) Cyanidin-3-O-rutinoside, and (c) Cyanidin-3-O-rutinoside).
Figure 3(A) HPLC chromatogram and (B) structures of black raspberry anthocyanins detected at 280 nm.
Identification of phenolic compounds in black raspberry by HPLC-FT-ICR MS/MS and peaks numbers as in Figure 1.
| No. | RT | Observed | Calculated | Error | MS/MS | Formula | Identification | References |
|---|---|---|---|---|---|---|---|---|
| 1 | 19.85 | 581.15071 | 581.15010 | −1.03 | 287.05478 | C26H29O15 | Cyanidin- | [ |
| 2 | 21.99 | 449.10530 | 449.10784 | −0.71 | 287.05440 | C21H21O11 | Cyanidin- | [ |
| 3 | 23.51 | 727.20315 | 727.20811 | −1.04 | 287.05455 | C32H39O19 | Cyanidin- | [ |
| 4 | 25.78 | 595.16217 | 595.16575 | −0.23 | 287.05520 | C27H31O15 | Cyanidin- | [ |
| 5 | 29.50 | 433.11031 | 433.11292 | −0.16 | 271.05945 | C21H21O10 | Pelargonidin- | [ |
| 6 | 34.50 | 579.16687 | 579.17083 | −1.46 | 271.05954 | C27H31O14 | Pelargonidin- | [ |
| 7 | 36.10 | 609.18196 | 609.18140 | −0.93 | 301.07027 | C28H33O15 | Peonidin- | [ |
Effect of BRAs on the activity of biochemical parameters.
| Treatment Group | Final Weight (g) | Liver Index (%) | AST (U/L) | ALT (U/L) | CHOL (U/L) | TBIL (U/L) | LDL (U/L) |
|---|---|---|---|---|---|---|---|
| (a) Subacute ALD mice | |||||||
| Control | 35.11 ± 0.91 | 4.10 ± 0.21 | 81.40 ± 1.45 | 28.60 ± 1.56 | 1.92 ± 0.78 | 1.23 ± 0.52 | 0.28 ± 0.18 |
| Model | 34.67 ± 0.62 * | 5.07 ± 0.47 *** | 114.14 ± 2.17 *** | 57.71 ± 1.14 *** | 2.59 ± 1.01 *** | 1.73 ± 1.08 *** | 0.48 ± 0.15 *** |
| Low-dose BRAs | 35.18 ± 0.72 | 4.86 ± 0.22 ### | 107.13 ± 2.02 # | 41.50 ± 1.11 ## | 2.44 ± 1.13 # | 1.45 ± 1.02 ### | 0.42 ± 0.13 |
| Middle-dose BRAs | 35.24 ± 0.64 | 4.54 ± 0.38 ### | 101.67 ± 1.67## | 37.33 ± 1.03 ### | 2.39 ± 0.76 ### | 1.31 ± 0.94 ### | 0.40 ± 0.12 |
| High-dose BRAs | 35.12 ± 0.56 | 4.33 ± 0.32 ### | 87.13 ± 1.32 ### | 31.38 ± 0.97 ### | 2.14 ± 0.81 ### | 1.26 ± 0.75 ### | 0.38 ± 0.09 # |
| (b) Acute ALD mice | |||||||
| Control | 35.14 ± 0.87 | 4.19 ± 0.22 | 81.43 ± 1.47 | 28.58 ± 1.26 | 1.94 ± 0.88 | 1.25 ± 0.49 | 0.29 ± 0.19 |
| Model | 34.78 ± 0.57 * | 5.26 ± 0.41 *** | 133.27 ± 2.74 *** | 62.56 ± 1.45 *** | 3.31 ± 1.45 *** | 1.94 ± 0.98 *** | 0.80 ± 0.54 *** |
| Low-dose BRAs | 35.13 ± 0.63 | 4.95 ± 0.34 ### | 122.16 ± 2.14 ## | 52.64 ± 1.32 ## | 3.06 ± 1.23 ## | 1.85 ± 0.79 | 0.73 ± 0.46 |
| Middle-dose BRAs | 35.11 ± 0.45 | 4.73 ± 0.31 ### | 113.77 ± 1.78 ### | 44.43 ± 1.13 ### | 3.01 ± 1.17 ### | 1.61 ± 0.54 # | 0.65 ± 0.43 |
| High-dose BRAs | 35.19 ± 0.55 | 4.29 ± 0.28 ### | 92.75 ± 1.23 ###,* | 32.80 ± 1.07 ### | 2.28 ± 1.02 ### | 1.33 ± 0.51 ### | 0.48 ± 0.32 # |
Values are the mean ± standard deviation of 10 determinations. Compared with control: *, p < 0.05; ***, p < 0.001. Compared with model: #, p < 0.05; ##, p < 0.01; ###, p < 0.001.
Figure 4(A,B) The histological analysis of BRAs on subacute (A) and acute (B) alcohol-induced liver injury (×500 magnification): (a) control group, (b) model group, (c) low-dose BRA group, (d) middle-dose BRA group, and (e) high-dose BRA group. (C) NF-κB and TGF-β expression in the liver tissue. (D) Morphological changes in HepG2 cells. (E) The induction of apoptosis was determined by flow cytometric analysis with Annexin V-FITC and PI-staining. (F) Effects of cyanidin-3-O-rutinoside and BRAs on the expression of various cell apoptosis proteins in HepG2 cells.
Cytotoxic activity of anthocyanins on HSC, HepG2, Hep3B, and GES-1.
| Cell Line | IC50 ( | |||
|---|---|---|---|---|
| BRAs | Cyanidin- | Silymarin | Mitomycin C | |
| t-HSC/Cl-6 | 202.91 ± 10.17 a | 17.87 ± 2.43 a | 192.19 ± 14.22 a | - |
| HepG2 | 198.63 ± 9.68 a | 13.46 ± 1.78 a | - | 8.06 ± 1.12 a |
| Hep3B | 181.00 ± 12.34 a | 9.95 ± 1.81 a | - | 8.01 ± 1.15 a |
| GSE-1 | 335.10 ± 18.65 a | 37.14 ± 4.07 a | - | 9.11 ± 1.26 a |
a μg/mL, b μM.